This inventor holds 4 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Abbvie Inc., Abbott Laboratories Corporation. Active years: 2011-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chicago, IL (US) (2011 - 2013)
- Highland Park, IL (US) (2014 - 2015)
Company Filing History:
Years Active: 2011-2015
Title: Megan E Gallagher: Innovator in Cannabinoid Research
Introduction
Megan E Gallagher is a prominent inventor based in Highland Park, IL (US). She has made significant contributions to the field of cannabinoid research, holding a total of 4 patents. Her work focuses on developing compounds that interact with cannabinoid receptors, which have potential therapeutic applications.
Latest Patents
Megan's latest patents include innovative compounds designed as cannabinoid receptor ligands. The first patent describes compounds of formula (I), along with their pharmaceutically acceptable salts, prodrugs, and combinations thereof. These compounds are aimed at treating various conditions and disorders. Additionally, her work encompasses compounds of formula (II), which also includes pharmaceutical salts and prodrugs, further expanding the potential applications of her research.
Career Highlights
Throughout her career, Megan has worked with notable companies such as AbbVie Inc. and Abbott Laboratories Corporation. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and cannabinoid research.
Collaborations
Megan has collaborated with esteemed colleagues, including Alan S Florjancic and Michael J Dart. These partnerships have contributed to her innovative research and the advancement of cannabinoid-related therapies.
Conclusion
Megan E Gallagher is a trailblazer in cannabinoid research, with a strong portfolio of patents and a career marked by significant contributions to the field. Her work continues to pave the way for new therapeutic options in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile